Reports
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States
Americas
Future Market Insights, Inc.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
MEA
Future Market Insights
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom
Asia Pacific
Future Market Insights
IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India
The global peptide antibiotics market was valued at around US$ 4.4 Billion at the end of 2021. The market is projected to register a 6.6% CAGR and top a valuation of US$ 8.3 Billion by 2032.
The market for peptide antibiotics is likely to thrive in the future given the rising incidence of disorders such as bloodstream infections, hospital-acquired infections, and bacterial skin infections.
Peptide antibiotics are peptides having strong antibacterial and antifungal properties. Peptide antibiotics are an essential part of the innate immune system, which living organisms rely on as their first line of defense against invading pathogens. The primary sites for the synthesis of these peptides are tissues that have direct environmental contact, such as the skin, gut, and lungs.
Peptide antibiotics are anti-infective and anti-tumor medicines that contain polypeptide chains. Peptide antibiotics come in two varieties: ribosomally synthesized peptide antibiotics and non-ribosomally synthesized peptide antibiotics. The advantages of peptide antibiotics include high specificity, high efficacy, and low toxicity.
Attributes |
Details |
Peptide Antibiotics Market Value in 2021 |
US$ 4.4 Billion |
Peptide Antibiotics Market Value in 2032 |
US$ 8.3 Billion |
Peptide Antibiotics Market CAGR (2022 to 2032) |
6.6% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
In light of factors like rising peptide antibiotic research & development activity and a high number of product approvals, the market is anticipated to experience potential growth. Additionally, the potential for side effects from traditional antibiotics and the rise in occurrences of antimicrobial resistance are anticipated to fuel the market throughout the forecast period.
Over the projected period, rising rates of cancer and other related infections are expected to spur growth. Some peptide antibiotics are prescribed to treat malignancies such as Hodgkin's lymphoma and a few different kinds of skin cancers. Globocan 2020 reports that there were 83,087 instances of Hodgkin's lymphoma and 5,44,352 cases of non-Hodgkin lymphoma. Due to doctor recommendations, it is anticipated that the effectiveness of various existing products would result in higher sales. BLEOMYCIN for injection is a combination of cytotoxic glycopeptide antibiotics, which is derived from the bacterium Streptomyces verticillus. It is utilized for the treatment of testicular cancer, squamous cell carcinoma, and other types of lymphomas.
The peptide antibiotics market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.
The largest market for peptide antibiotics is in North America. Increased Research and Development activities in the region are anticipated to fuel the market over the projected period due to the region's increased demand for antibiotics.
The European peptide antibiotics industry is likewise anticipated to experience profitable expansion. Some of the important drivers of growth are the existence of major manufacturers and strategic initiatives undertaken by prominent companies.
The East Asian region is predicted to show lucrative growth owing to increasing rates of infectious disease and the vast presence of the elderly population.
Pfizer Inc., Merck & Co., Inc., AbbVie Inc, GSK Group of Companies, Sandoz International GmbH, Xellia Pharmaceuticals, AuroMedics Pharma LLC, Theravance Biopharma, Novartis, GlaxoSmithKline, Eli Lilly.
Report Attributes |
Details |
Growth Rate |
CAGR of 6.6% from 2022 to 2032 |
Base Year for Estimation |
2021 |
Historical Data |
2012 to 2021 |
Forecast Period |
2022 to 2032 |
Qualitative Units |
Revenue in USD Billion, and CAGR from 2022 to 2032 |
Report Coverage |
Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
Segment Covered |
|
Region Covered |
|
Key Countries Profiled |
|
Key Players |
|
Customization |
Available Upon Request |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The global peptide antibiotics market is anticipated to register a CAGR of 6.6% during the forecast period.
The global peptide antibiotics market is projected to be about US$ 8.3 Billion by the end of the year 2032.
Explore Healthcare Insights
View Reports